Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Terminated 2Unknown 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3Genitourinary 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Pituitary Neoplasms 2Pituitary ACTH Hypersecretion 1Central Nervous System Neoplasms 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Rosiglitazone × Endocrine × Clear all
NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled 4 charts
CNSEndocrine

Pituitary Neoplasms, Central Nervous System Neoplasms

NCT00612066 2020-08-06

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 5 charts
Endocrine

Pituitary ACTH Hypersecretion

NCT03309319 2017-10-13

A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Huashan Hospital

Phase NA Unknown
24 enrolled
Endocrine

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡